Restricted accessResearch articleFirst published online 2012-11
Ex Vivo Generated Natural Killer Cells Acquire Typical Natural Killer Receptors and Display a Cytotoxic Gene Expression Profile Similar to Peripheral Blood Natural Killer Cells
Ex vivo differentiation systems of natural killer (NK) cells from CD34+ hematopoietic stem cells are of potential importance for adjuvant immunotherapy of cancer. Here, we analyzed ex vivo differentiation of NK cells from cord blood-derived CD34+ stem cells by gene expression profiling, real-time RT-PCR, flow cytometry, and functional analysis. Additionally, we compared the identified characteristics to peripheral blood (PB) CD56bright and CD56dim NK cells. The data show sequential expression of CD56 and the CD94 and NKG2 receptor chains during ex vivo NK cell development, resulting finally in the expression of a range of genes with partial characteristics of CD56bright and CD56dim NK cells from PB. Expression of characteristic NK cell receptors and cytotoxic genes was mainly found within the predominant ex vivo generated population of NKG2A+ NK cells, indicating the importance of NKG2A expression during NK cell differentiation and maturation. Furthermore, despite distinct phenotypic characteristics, the detailed analysis of cytolytic genes expressed within the ex vivo differentiated NK cells revealed a pattern close to CD56dim NK cells. In line with this finding, ex vivo generated NK cells displayed potent cytotoxicity. This supports that the ex vivo differentiation system faithfully reproduces major steps of the differentiation of NK cells from their progenitors, constitutes an excellent model to study NK cell differentiation, and is valuable to generate large-scale NK cells appropriate for immunotherapy.
Get full access to this article
View all access options for this article.
References
1.
Di SantoJP. 2008. Natural killer cells: diversity in search of a niche. Nat Immunol, 9:473–475.
VivierE, RauletDH, MorettaA, CaligiuriMA, ZitvogelL, LanierLL, YokoyamaWM, UgoliniS. 2011. Innate or adaptive immunity? The example of natural killer cells. Science, 331:44–49.
4.
CooperMA, FehnigerTA, CaligiuriMA. 2001. The biology of human natural killer-cell subsets. Trends Immunol, 22:633–640.
5.
De MariaA, BozzanoF, CantoniC, MorettaL. 2011. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A, 108:728–732.
6.
RomagnaniC, JuelkeK, FalcoM, MorandiB, D'AgostinoA, CostaR, RattoG, ForteG, CarregaPet al.2007. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol, 178:4947–4955.
7.
LjunggrenHG, MalmbergKJ. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol, 7:329–339.
8.
SutluT, AliciE. 2009. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med, 266:154–181.
9.
SpanholtzJ, TordoirM, EissensD, PreijersF, van der MeerA, JoostenI, SchaapN, de WitteTM, DolstraH. 2010. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One, 5:e9221.
10.
SpanholtzJ, PreijersF, TordoirM, TrilsbeekC, PaardekooperJ, de WitteT, SchaapN, DolstraH. 2011. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One, 6:e20740.
11.
NK cells as post consolidation therapie in AML. www.trialregister.nl/trialreg/admin/rctview.asp?.TC=2818
BrostjanC, BellonT, SobanovY, Lopez-BotetM, HoferE. 2002. Differential expression of inhibitory and activating CD94/NKG2 receptors on NK cell clones. J Immunol Methods, 264:109–119.
14.
BilbanM, Ghaffari-TabriziN, HintermannE, BauerS, MolzerS, ZorattiC, MalliR, SharabiA, HidenUet al.2004. Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci, 117:1319–1328.
15.
BilbanM, HeintelD, ScharlT, WoelfelT, AuerMM, PorpaczyE, KainzB, KroberA, CareyVJet al.2006. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia, 20:1080–1088.
16.
BlombergK, GranbergC, HemmilaI, LovgrenT. 1986. Europium-labelled target cells in an assay of natural killer cell activity. I. A novel non-radioactive method based on time-resolved fluorescence. J Immunol Methods, 86:225–229.
17.
GrzywaczB, KatariaN, SikoraM, OostendorpRA, DzierzakEA, BlazarBR, MillerJS, VernerisMR. 2006. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood, 108:3824–3833.
18.
SivakumarPV, GunturiA, SalcedoM, SchatzleJD, LaiWC, KurepaZ, PitcherL, SeamanMS, LemonnierFAet al.1999. Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell development. J Immunol, 162:6976–6980.
19.
KeatingGM. 2010. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs, 70:1445–1476.
20.
CurtiA, RuggeriL, D'AddioA, BontadiniA, DanE, MottaMR, TrabanelliS, GiudiceV, UrbaniEet al.2011. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood, 118:3273–3279.
KimS, IizukaK, KangHS, DokunA, FrenchAR, GrecoS, YokoyamaWM. 2002. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol, 3:523–528.
23.
PuzanovIJ, BennettM, KumarV. 1996. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells. J Immunol, 157:4282–4285.
24.
HallerO, KiesslingR, OrnA, WigzellH. 1977. Generation of natural killer cells: an autonomous function of the bone marrow. J Exp Med, 145:1411–1416.
25.
MillerJS, AlleyKA, McGlaveP. 1994. Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor. Blood, 83:2594–2601.
26.
MrozekE, AndersonP, CaligiuriMA. 1996. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood, 87:2632–2640.
27.
HuntingtonND, VosshenrichCA, Di SantoJP. 2007. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol, 7:703–714.
28.
StrowigT, ChijiokeO, CarregaP, ArreyF, MeixlspergerS, RamerPC, FerlazzoG, MunzC. 2010. Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood, 116:4158–4167.
29.
FreudAG, YokohamaA, BecknellB, LeeMT, MaoHC, FerketichAK, CaligiuriMA. 2006. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med, 203:1033–1043.
ClarksonSB, OryPA. 1988. CD16. Developmentally regulated IgG Fc receptors on cultured human monocytes. J Exp Med, 167:408–420.
32.
ElpekKG, RubinsteinMP, Bellemare-PelletierA, GoldrathAW, TurleySJ. 2010. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc Natl Acad Sci U S A, 107:21647–21652.
33.
HuntingtonND, LegrandN, AlvesNL, JaronB, WeijerK, PletA, CorcuffE, MortierE, JacquesY, SpitsH, Di SantoJP. 2009. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med, 206:25–34.
34.
SoderquestK, PowellN, LuciC, van RooijenN, HidalgoA, GeissmannF, WalzerT, LordGM, Martin-FontechaA. 2011. Monocytes control natural killer cell differentiation to effector phenotypes. Blood, 117:4511–4518.
35.
Lopez-BotetM, BellonT, LlanoM, NavarroF, GarciaP, de MiguelM. 2000. Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol, 61:7–17.
36.
GumaM, CabreraC, ErkiziaI, BofillM, ClotetB, RuizL, Lopez-BotetM. 2006. Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis, 194:38–41.
37.
CooleyS, XiaoF, PittM, GleasonM, McCullarV, BergemannTL, McQueenKL, GuethleinLA, ParhamP, MillerJS. 2007. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood, 110:578–586.
38.
WendtK, WilkE, BuynyS, BuerJ, SchmidtRE, JacobsR. 2006. Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells. J Leukoc Biol, 80:1529–1541.
39.
HannaJ, BechtelP, ZhaiY, YoussefF, McLachlanK, MandelboimO. 2004. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol, 173:6547–6563.
40.
BhatR, WatzlC. 2007. Serial killing of tumor cells by human natural killer cells—enhancement by therapeutic antibodies. PLoS One, 2:e326.
41.
RubnitzJE, InabaH, RibeiroRC, PoundsS, RooneyB, BellT, PuiCH, LeungW. 2010. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol, 28:955–959.
42.
MillerJS, SoignierY, Panoskaltsis-MortariA, McNearneySA, YunGH, FautschSK, McKennaD, LeC, DeforTEet al.2005. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 105:3051–3057.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
